 |
 |
 |
 This year Shin Nippon Biomedical Laboratories, Ltd. enters the 53rd year
since its foundation as the first Japanese contract research organization
(CRO) in 1957. Since then, we have become able to support pharmaceutical
companies with a full range of drug development services, including safety
research, clinical pharmacology, and clinical trials. Currently, SNBL Group
employs more than one thousand professionals and is the largest CRO in
Japan. I must thank our clients for their trust, strong support, and close
and heartfelt cooperation that have enabled our growth over the years.
SNBL Group has facilities and offices not only in Japan but also in the
United States, Europe and China. The Group is proud of its world-ranking
state-of-the-art facilities and technology that provide reliable support
for research and drug development for a wide variety of diseases.
|
SNBL's company policy is to value the environment, life and people. It
is expressed in the three colors of our company logo:
- Sky Blue stands for our environment. It symbolizes a clear, beautiful sky and the
Earth, and expresses our stance in protecting our beautiful environment.
- Green stands for life. It reflects our awe of life and our commitment to developing
life-saving medicine.
- Deep blue symbolizes people. It signifies the deep sea from which human life was
born, and reminds us to value humanity.
We believe that our lives and our bodies are mutually beneficial. Through
supporting drug development, we contribute to a better life for all people.
Our extensive research achievements enable us to support successful development
of effective new drugs. Each employee individually works to protect the
environment, and each employee contributes to saving precious lives. We
believe that to be our social mission.
With the rapid advance of scientific technology, the environment of new
drug discovery and development is changing dramatically. To adapt to these
changes, SNBL Group is actively supporting scientists in universities and
ventures around the world who share our mission and policy. In recent years,
we have aggressively developed 'Translational Research Operations', establishing
partnerships to support talented researchers and bioventures with exciting
ideas and valuable skill sets. We firmly believe our untiring efforts to
fulfill our mission in good faith will bring satisfaction to our clients,
and make a valuable contribution to humanity and society. We sincerely
wish to keep our clients' implicit trust in our services and firmly hope
that our collaborations will benefit customers and patients.
|
| |
Ryoichi Nagata, M.D., Ph.D.,FFPM
President and CEO
|
|